Friday, July 10, 2026
🇺🇸 FDA

pharma · Non-muscle Invasive Bladder Cancer · Non-Muscle Invasive Bladder Cancer

ImmunityBio

Immunitybio Ireland Limited

NovaPharmaNews editorial coverage mentioning ImmunityBio — regulatory, clinical, and market analysis.

Website Investor relations
San Diego, USA HQ
2014 Founded
625 Employees
EMA registrant Type
Company details
Status
Public
HQ
San Diego, USA
Founded
2014
Employees
625
Programs
2
Drugs
5
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning ImmunityBio — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning ImmunityBio — regulatory, clinical, and market analysis.

All News Analysis

1 articles

ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles
Critical impact Analysisbladder cancerJun 2, 2026

ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles

FDA · bladder cancer · 9 min

ImmunityBio is navigating a complex regulatory landscape for its bladder cancer therapy, Anktiva. This article provides insights into upcoming FDA decisions and their impact on the pharmaceutical industry.

Dr. Elena Rossi

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.